ZNF2 Inhibitors
Chemical inhibitors of the protein ZNF2 operate through the targeted disruption of its phosphorylation state, a post-translational modification essential for its activity. Alsterpaullone, Kenpaullone, Roscovitine, and Flavopiridol can inhibit a range of cyclin-dependent kinases (CDKs) which are pivotal for the cell cycle progression. The inhibition of these kinases by these compounds can hinder the phosphorylation of ZNF2. For instance, Alsterpaullone has an affinity for CDK1, CDK2, and CDK5, all of which are integral to the cell cycle, and their inhibition can directly reduce the phosphorylation of proteins like ZNF2 that are dependent on the cell cycle for their function. Similarly, Roscovitine's selective inhibition of CDK2, CDK7, and CDK9 can suppress the phosphorylation of ZNF2. Flavopiridol, with a broader spectrum, targets CDK1, CDK2, CDK4, CDK6, and CDK9, offering a more comprehensive blockade against ZNF2's activation via phosphorylation.
On the other hand, compounds such as Indirubin-3'-monoxime, Olomoucine, and Purvalanol A show selective inhibition of CDKs, which can disrupt the phosphorylation of ZNF2. Indirubin-3'-monoxime's action is not only limited to CDKs but also includes glycogen synthase kinase 3 (GSK-3), which could further modulate the phosphorylation status of ZNF2. Olomoucine's selectivity towards CDK1, CDK2, and CDK5 can specifically interfere with the phosphorylation cycle of ZNF2. Purvalanol A, being a potent inhibitor of CDK1 and CDK2, can also lead to reduced activity of ZNF2 by similar mechanisms. Furthermore, Dinaciclib, Ribociclib, Palbociclib, and Abemaciclib, which target CDK4 and CDK6, can inhibit the phosphorylation of ZNF2, thereby impacting its activity. Dinaciclib, in particular, with its strong inhibition of CDK1, CDK2, CDK5, and CDK9, can significantly reduce the phosphorylation and consequent activity of ZNF2. These inhibitors collectively demonstrate the capability to interfere with the phosphorylation processes necessary for the functional activity of ZNF2.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs) such as CDK1, CDK2, CDK5, which are essential for cell cycle progression. Inhibition of these CDKs can disrupt the cell cycle and hence potentially inhibit the activity of ZNF2 by preventing its necessary cell cycle-dependent phosphorylation. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $60.00 $150.00 $226.00 $495.00 | 1 | |
Kenpaullone, another CDK inhibitor, similarly blocks the activity of cyclin-dependent kinases which could lead to the inhibition of ZNF2 through the same mechanism as alsterpaullone, disrupting necessary phosphorylation processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine selectively inhibits CDKs, particularly CDK2, CDK7, and CDK9. By inhibiting these kinases, roscovitine may inhibit the phosphorylation of ZNF2, which is critical for its activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Indirubin-3'-monoxime is an inhibitor of CDKs as well as glycogen synthase kinase 3 (GSK-3). By targeting these kinases, it may inhibit the phosphorylation state of ZNF2, which is necessary for its full activation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits several CDKs, including CDK1, CDK2, CDK4, CDK6, and CDK9. This inhibition can prevent the cell cycle progression and thus inhibit ZNF2 activity by not allowing the phosphorylation that may be essential for its function. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDK1, CDK2, and CDK5. This selectivity can lead to the inhibition of ZNF2 by impeding the phosphorylation events required for its proper function. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a potent inhibitor of CDK1 and CDK2. By specifically inhibiting these kinases, it can hinder the phosphorylation and thereby the activity of ZNF2. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib strongly inhibits CDK1, CDK2, CDK5, and CDK9. This broad inhibition of CDKs can prevent the phosphorylation of ZNF2, thus inhibiting its activity. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4 and CDK6. By inhibiting these kinases, Ribociclib may inhibit the phosphorylation of ZNF2, which could be crucial for its activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is an inhibitor of CDK4 and CDK6. The inhibition of these kinases can lead to the inhibition of ZNF2 activity by preventing necessary phosphorylation processes. | ||||||